Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received March 3, 2016
- Accepted in final form June 29, 2016
- First Published August 2, 2016.
Author Disclosures
- Joakim Bergman, MD,
- Ann Dring, PhD,
- Henrik Zetterberg, MD,
- Kaj Blennow, MD,
- Niklas Norgren, PhD,
- Jonathan Gilthorpe, PhD,
- Tommy Bergenheim, MD and
- Anders Svenningsson, MD
- Joakim Bergman, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ann Dring, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Henrik Zetterberg, MD,
NONE
NONE
NONE
Journal of Alzheimer's Disease, Associate Editor Alzheimer's & Dementia, Associate Editor DADM, Associate Senior Editor
NONE
NONE
NONE
NONE
NONE
HZ is co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg.
NONE
NONE
(1) The Swedish Research Council (K2010-63P-21562-01-4, K2011-61X-20401-05-6); (2) Swedish State Support for Clinical Research (ALFGBG-144341); (3) VINNOVA; (4) the Knut and Alice Wallenberg Foundation; (5) the European Research Council; and (6) Frimurarestiftelsen
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kaj Blennow, MD,
Dr Blennow has served at advisory boards or as a consultant for Eli Lilly, IBL International, and Roche Diagnostics.
NONE
Fujirebio Europe
NONE
NONE
NONE
NONE
Novartis
NONE
Co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg
NONE
NONE
The Research Council, Sweden (project # 14002) and LUA/ALF project, V?stra G?talandsregionen, Sweden (project # ALFGBG-11019)
NONE
The Torsten S?derberg Foundation at the royal Swedish Academy of Sciences, the Alzheimer Foundation, Sweden, the Stiftelsen f?r Gamla Tj?narinnor, Stockholm, Sweden and Hj?rnfonden, Sweden.
NONE
NONE
NONE
NONE
NONE
NONE
- Niklas Norgren, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
I am employed by UmanDiagnostics AB (been working for UmanDiagnostics since 2006)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jonathan Gilthorpe, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tommy Bergenheim, MD and
NONE
NONE
NONE
Member of editorial board J Neurooncology
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Swedish Cancer Society
NONE
NONE
NONE
NONE
NONE
NONE
- Anders Svenningsson, MD
Served in advisory board for Sanofi-Genzyme
NONE
1. Travel and congress expenses paid for by BiogenIdec, Sanofi- Genzyme, Novartis and Baxter Medical 2. Speaker honoraria from BiogenIdec and Sanofi-Genzyme
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Non-conditional grant received from BiogenIdec
NONE
NONE
National Multiple Sclerosis Society, Progressive MS Alliance, research grant no PA0185
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Pharmacology and Clinical Neuroscience (J.B., A.D., J.G., T.B., A.S.), Umeå University; Institute of Neuroscience and Physiology (H.Z., K.B.), Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Department of Molecular Neuroscience (H.Z.), UCL Institute of Neurology, Queen Square, London, UK; UmanDiagnostics AB (N.N.), Umeå; and Department of Clinical Sciences (A.S.), Danderyd Hospital, Karolinska Institutet, Danderyd Hospital AB, Stockholm, Sweden.
- Correspondence to Dr. Svenningsson: anders.svenningsson{at}ki.se
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Ann Yeh and Dr. Daniela Castillo Villagrán
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSDMitsuru Watanabe, Yuri Nakamura, Zuzanna Michalak et al.Neurology, August 30, 2019 -
Articles
Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosisC. E. Teunissen, E. Iacobaeus, M. Khademi et al.Neurology, April 13, 2009 -
Article
Intrathecal treatment trial of rituximab in progressive MSAn open-label phase 1b studyJoakim Bergman, Joachim Burman, Jonathan D. Gilthorpe et al.Neurology, October 10, 2018 -
Article
Neurofilament light chain level is a weak risk factor for the development of MSGeorgina Arrambide, Carmen Espejo, Herena Eixarch et al.Neurology, August 12, 2016